<DOC>
	<DOCNO>NCT02487407</DOCNO>
	<brief_summary>In double-blind , cross-over part study , ODM-109 capsule placebo capsule ODM-109 administer 2 week separate 19-23 day wash-out period . During treatment period double-blind cross-over part , baseline visit ( day 1 ) 2 visit ( 5 ± 2 14 ± 2 day ) start study treatment . After complete 3rd treatment period , subject continue open-label follow-up part 6 month . During open-label follow-up , visit 1 , 3 6 month . An end-of-study visit take place 14-25 day last study treatment administration subject . The study duration 13-14 week double-blind cross-over part , 9-10 month entire study include 6 month open-label follow-up . The number randomise study subject plan approximately 54 cross-over comparison . The maximum number subject exceed 70 . Primary objective investigate efficacy oral ODM-109 respiratory function patient amyotrophic lateral sclerosis ( ALS ) .</brief_summary>
	<brief_title>Effects ODM-109 Respiratory Function Patients With Amyotrophic Lateral Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Motor Neuron Disease</mesh_term>
	<mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
	<mesh_term>Simendan</mesh_term>
	<criteria>Written inform consent ( IC ) participation study obtain subject ( subject 's next kin , caregiver , legally acceptable representative case study subject him/herself sign IC due severe muscle weakness ) . Age least 18 year . Male female subject diagnosis laboratory support probable , probable definite ALS accord El Escorial revise criterion ( Brooks BR et al. , 2000 ) . Full electromyogram ( EMG ) report available compatible ALS accord experienced neurophysiologist . Ability swallow study treatment capsule . An upright ( sit position ) SVC 6090 % predict value age , height sex screen visit . Normal oxygen saturation daytime ( measure ≥ 95 % steady state reach reliable read ) sit position measure pulse oximetry . Disease duration symptom onset ( define first muscle weakness dysarthria ) 1248 month . Using riluzole . The dose must stable least 4 week prior screen dose 50 mg b.i.d . Subject cause neuromuscular weakness exclude . Subject diagnosis another neurodegenerative disease ( e.g . Parkinson 's Alzheimer 's disease ) . Assisted ventilation gastrostomy type precede 3 month prior screen predict require within randomise , doubleblind crossover part study . Recorded diagnosis evidence major psychiatric diagnosis , significant cognitive impairment clinically evident dementia . Any major surgery within 1 month screen visit patient schedule major surgery plan study period . Potassium &lt; 3.7 mmol/l &gt; 5.5 mmol/l screening . Creatinine &gt; 170 μmol/l screen dialysis . Blood haemoglobin &lt; 10 g/dl screening . Clinically significant hepatic impairment discretion investigator . Women reproductive age without negative pregnancy test without commitment use acceptable method barrier hormonal contraception ( e.g . condom , diaphragm , oral contraceptive long act progestin agent ) , sexually active study , 1 month last dose study treatment . Women postmenopausal ( 1 year since last menstrual cycle ) , surgically sterilise undergone hysterectomy consider reproductive include . Known hypersensitivity levosimendan . Administration levosimendan within 30 day prior screen visit . Patients history botulinum toxin treatment reason . Patients known history human immunodeficiency virus infection . History significant arrhythmias cardiac event Any clinically significant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , neurological psychiatric disorder major concurrent illness opinion investigator could interfere interpretation study result constitute health risk subject he/she take part study . Blood donation loss significant amount blood within 60 day prior screen . Participation clinical trial experimental treatment within 30 day prior screen visit previous participation present study . Any condition opinion investigator could interfere interpretation study result constitute health risk subject he/she take part study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>